Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

Preetesh Jain; Sa Wang; Keyur P. Patel; Nawid Sarwari; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek

doi:10.1016/j.leukres.2017.05.018

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

Preetesh Jain, Sa Wang, Keyur P. Patel, Nawid Sarwari, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

Original language	English (US)
Pages (from-to)	105-109
Number of pages	5
Journal	Leukemia Research
Volume	59
DOIs	https://doi.org/10.1016/j.leukres.2017.05.018
State	Published - Aug 2017
Externally published	Yes

Keywords

Mast cell leukemia
Systemic mastocytosis

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2017.05.018

Cite this

@article{6bce52d7e45f497bafcdd2fb2afbeb8d,

title = "Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome",

abstract = "Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.",

keywords = "Mast cell leukemia, Systemic mastocytosis",

author = "Preetesh Jain and Sa Wang and Patel, {Keyur P.} and Nawid Sarwari and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",

note = "Funding Information: This study was supported in part by the NIH/NCI under award number P30CA016672 and by the NCI under award number P01CA049639. Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = aug,

doi = "10.1016/j.leukres.2017.05.018",

language = "English (US)",

volume = "59",

pages = "105--109",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Mast cell leukemia (MCL)

T2 - Clinico-pathologic and molecular features and survival outcome

AU - Jain, Preetesh

AU - Wang, Sa

AU - Patel, Keyur P.

AU - Sarwari, Nawid

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2017/8

Y1 - 2017/8

N2 - Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

AB - Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

KW - Mast cell leukemia

KW - Systemic mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=85020240266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020240266&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.05.018

DO - 10.1016/j.leukres.2017.05.018

M3 - Article

C2 - 28599188

AN - SCOPUS:85020240266

SN - 0145-2126

VL - 59

SP - 105

EP - 109

JO - Leukemia Research

JF - Leukemia Research

ER -

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this